Development of a Prognostic Prediction Model for Clinically Significant Prostate Cancer Based on Lesion Zone and Apparent Diffusion Coefficient Value Quantification - 07/04/26
, Penny S. Reynolds b, Shay Rajavel c, Kunal Hanchate c, William Snead a, John M. DiBianco a, Jason Joseph a, Paul Crispen a, Padraic O'Malley a, Joseph R. Grajo a, d, Sara M. Falzarano a, e, Thomas F. Stringer a, Li-Ming Su a, Christopher J. Weight f, Tarik Benidir aABSTRACT |
Objective |
To guide biopsy decision making via a predictive model for clinically significant prostate cancer (csPCa) in men with positive imaging (PI-RADS 3-5). We aim to elucidate the influence of zone on the predictive accuracy of PI-RADS v2.1, establish a threshold of quantified apparent diffusion coefficient (ADC) values suspicious for csPCa, and create a logistic-regression model, unique in its inclusion of lesion zone and quantified ADC.
Methods |
Data were retrospectively collected from a single cancer center, with institutional review board review and exemption waiver, on a lesion-level retrospective analysis of prostate multiparametric magnetic resonance imaging (mpMRI) of N = 429 men, harboring N = 546 lesions. MRIs were read and reviewed by a fellowship-trained genitourinary/abdominal imaging radiologist. Pathologic analysis was conducted by a fellowship-trained genitourinary pathologist. All statistical analysis including predictive modeling were conducted by an expert biostatistician.
Results |
On multivariate analysis, zone (PZ as compared to TZ) was a predictor of csPCa (OR 2.58, 95% CI 1.50-4.44, P < .0005). A 700 µm 2 /s ADC value cutoff in isolation had an AUC of 0.56, but our combined model, bolstered by clinical and imaging data, including zone and prostate-specific antigen density, yielded an AUC of 0.78, at an ADC value cutoff of 947 µm 2 /s. In application, simulated scenarios yielded probabilities between 16% and 82%, therefore above a biopsy omission threshold of 10% or less.
Conclusion |
Prostate zone and ADC value quantification each independently contribute to csPCa predictability, but no simulated use of the model yielded biopsy-omission thresholds for patients with MRI visible lesions.
Le texte complet de cet article est disponible en PDF.Plan
| 1 | Analytical reporting checklist completed: TRIPOD |
Vol 210
P. 86-90 - avril 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
